Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

Blood (2016) 128 (22): 4416.

https://doi.org/10.1182/blood.V128.22.4416.4416

Published: 2016

Journal Articles

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Leo Rasche, MD, Amy Buros, PhD, Niels Weinhold, PhD, Caleb K. Stein, MS, James E McDonald, Shweta S. Chavan, PhD, Edgardo Angtuaco, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4431.

https://doi.org/10.1182/blood.V128.22.4431.4431

Published: 2016

Journal Articles

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Antonio Branca, MD, Amy Buros, PhD, Donghoon Yoon, PhD, Larry J Suva, PhD, Niels Weinhold, PhD, Leo Rasche, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Cerisse Harcourt, APRN, OCN, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD, Maurizio Zangari, MD

Blood (2016) 128 (22): 4516.

https://doi.org/10.1182/blood.V128.22.4516.4516

Published: 2016

Journal Articles

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Blood (2016) 128 (22): 117.

https://doi.org/10.1182/blood.V128.22.117.117

Published: 2016

Journal Articles

Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression

Erming Tian, PhD, Jeffery Sawyer, Owen W Stephens, Ruslana Tytarenko, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 115.

https://doi.org/10.1182/blood.V128.22.115.115

Published: 2016

Journal Articles

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Sandra Susanibar, MD, Victoria Carlton, PhD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Katherine A. Kong, PhD, Gareth J Morgan, MD PhD, Daisy V. Alapat, MD, Carolina Schinke, MD

Blood (2016) 128 (22): 377.

https://doi.org/10.1182/blood.V128.22.377.377

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Shmuel Yaccoby, PhD, Pingping Qu, PhD, Syed Mehdi, Antje Hoering, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 2065.

https://doi.org/10.1182/blood.V128.22.2065.2065

Published: 2016

Journal Articles

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Brian Koss, Whitney Tevebaugh, Brian A Walker, PhD, Carolina Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MD PhD, Sarah K. Johnson, PhD

Blood (2016) 128 (22): 4438.

https://doi.org/10.1182/blood.V128.22.4438.4438

Published: 2016

Journal Articles

Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC

Jeffery Sawyer, Erming Tian, PhD, Brian A Walker, PhD, Niels Weinhold, PhD, Charles Swanson, Janet L Lukacs, Regina Binz, Gael Sammartino, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Maurizio Zangari, MD, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 3266.

https://doi.org/10.1182/blood.V128.22.3266.3266

Published: 2016

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

Journal Articles

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Blood (2015) 126 (23): 2979.

https://doi.org/10.1182/blood.V126.23.2979.2979

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

Blood (2015) 126 (23): 369.

https://doi.org/10.1182/blood.V126.23.369.369

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Sharmilan Thanendrarajan, MD, Caleb K. Stein, MS, Faith E Davies, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Carolina Schinke, MD, Sarah Waheed, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Niels Weinhold, PhD, Aasiya Matin, Pankaj Mathur, Meera Mohan, Muthukumar Radhakrishnan, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 3182.

https://doi.org/10.1182/blood.V126.23.3182.3182

Published: 2015

Journal Articles

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

James E McDonald, Marcus M Kessler, Michael Gardner, Amy Buros, PhD, Sarah Waheed, MD, James Ntambi, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Nathan Petty, MS, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Alan Mitchell, Antje Hoering, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 724.

https://doi.org/10.1182/blood.V126.23.724.724

Published: 2015

Journal Articles

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Meera Mohan, Rohan Samant, Larry J Suva, Corey O Montgomery, Daisy V. Alapat, MD, Roy Morello, Frits van Rhee, MD PhD, Sarah Waheed, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Christoph Heuck, MD, Yogesh Jethava, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Maurizio Zangari, MD

Blood (2015) 126 (23): 4193.

https://doi.org/10.1182/blood.V126.23.4193.4193

Published: 2015

Journal Articles

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Sharmilan Thanendrarajan, MD, Daisy V. Alapat, MD, Maurizio Zangari, MD, Carolina Schinke, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Adam Rosenthal, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 1843.

https://doi.org/10.1182/blood.V126.23.1843.1843

Published: 2015

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

NARROW

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only